RxDoctor Payments Data

Christopher Rankin, MD

Family Medicine · Zwolle, LANPI 1558368829

Payments from drug & device makers

$422in general payments, 2019–2025

Across 20 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galt Pharmaceuticals, LLC$110
  • AstraZeneca$47
  • Novartis$46
  • AbbVie$45
  • Novo Nordisk$44
  • Exact Sciences$38
  • plus $93 from 5 others

What the payments were for

  • Food & beverage$422100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Galt Pharmaceuticals, LLC1$110
AstraZeneca3$47
Novartis3$46
AbbVie3$45
Novo Nordisk3$44
Exact Sciences2$38
Lilly USA, LLC1$25
Recor Medical Inc1$24
Amgen1$18
GSK1$15
Abbott1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$422 in reported general payments places this provider in the 40th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$15,447
Medicare patients
47
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide13$17,252
JardianceEmpagliflozin11$14,287
EliquisApixaban14$13,774
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$3,533
Albuterol Sulfate HfaAlbuterol Sulfate63$2,535
Famotidine27$391
Gabapentin29$375
Ondansetron OdtOndansetron15$332
Hydroxyzine Hcl25$311
Rosuvastatin Calcium49$296
Tizanidine Hcl21$294
Levothyroxine Sodium36$264
Metoprolol Succinate25$261
Atorvastatin Calcium35$215
Losartan Potassium40$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$25$17,25213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Zwolle

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →